Pipeline 1
Novel combination Alzheimer's disease (AD) drug (NV909AD) is designed to target both anti-amyloid antibody and neuroinflammation in order to increase drug effectiveness to slow down cognitive decline of AD patients. (Clinical stage)
Pipeline 2
New anticancer drug (NV908) targeting extracellular matrix hyaluronic acid (HA) and CD44 axis in breast and lung Cancers are cancer-specific and remove highly overexpressed HA/CD44 barrier blocking from immune surveillance and chemotherapeutic agents for the treatment of breast and lung cancers patients. (Preclinical stage)
Pipeline 3
GLP-1 (glucagon-like peptide-1) complexed with turmeric/curcumin for oral anti-obesity drug, (NV911) will include clinical studies to see the effect of NV911 on weight loss when orally administered.
Pipeline 4
Lateral flow rapid kits of early diagnosis of Alzheimer's disease (feasibility test)
Pipeline 5
Lateral flow rapid kits of early diagnosis of breast cancer (feasibility test)
Based on our Testing Services established in ELISA techniques of early diagnosis of Alzheimer's and breast cancer, we are interested in the development of lateral flow rapid kits by converting ELISA techniques to lateral flow assay.
For development/partnership, contact yang@vancbiotechnology.com.